BiotechTube

XR-NTX 380 mg, intramuscular injection + Placebo intramuscular injection

ApprovedRecruiting
1 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Alcohol Use Disorder

Conditions

Alcohol Use Disorder, Alcoholism

Trial Timeline

Mar 7, 2022 → Jul 1, 2028

NCT ID
NCT05028062

About XR-NTX 380 mg, intramuscular injection + Placebo intramuscular injection

XR-NTX 380 mg, intramuscular injection + Placebo intramuscular injection is a approved stage product being developed by Alkermes for Alcohol Use Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05028062. Target conditions include Alcohol Use Disorder, Alcoholism.

What happened to similar drugs?

10 of 20 similar drugs in Alcohol Use Disorder were approved

Approved (10) Terminated (3) Active (8)
✅Seroquel XRAstraZenecaApproved
✅Acamprosate or NaltrexoneMerckApproved
✅Acamprosate + PlaceboMerckApproved
✅LevetiracetamUCBApproved
✅losartan (drug)LundbeckApproved
✅Selincro® 18 mg with continuous psychosocial support: Cohort ALundbeckApproved
✅nalmefeneLundbeckApproved

Hype Score Breakdown

Clinical
20
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05028062ApprovedRecruiting

Competing Products

20 competing products in Alcohol Use Disorder

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
32
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
32
TERN-101Terns PharmaceuticalsPhase 2
32
TERN-201Terns PharmaceuticalsPhase 1
26
IVA337 + IVA337 + PlaceboInventivaPhase 2
29
LanifibranorInventivaPhase 2
29
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
29
IVA337 + PlaceboInventivaPhase 3
41
LY686017 + PlaceboEli LillyPhase 2
35
LY3537031 + PlaceboEli LillyPhase 3
47
AD04 (ondansetron) + Matching placeboAdial PharmaceuticalsPhase 3
30
GODEX + PlaceboCelltrionPhase 3
47
Colesevelam HclDaiichi SankyoPhase 2
35
ASP9831 + PlaceboAstellas PharmaPhase 2
35
ASP8062 + PlaceboAstellas PharmaPhase 2
35
LY686017 + PlaceboEli LillyPhase 2
35
Mazdutide + PlaceboEli LillyPhase 2
42
opioid receptor kappa antagonistEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 2
35
LY2196044 + placeboEli LillyPhase 2
35